Farallon Capital Management LLC Protagonist Therapeutics, Inc Transaction History

Farallon Capital Management LLC

$18.8 Billion
Q4 2024

A detailed history of Farallon Capital Management LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Farallon Capital Management LLC holds 5,930,006 shares of PTGX stock, worth $228 Million. This represents 1.22% of its overall portfolio holdings.

Number of Shares

5,930,006

Holding current value

$228 Million

% of portfolio

1.22%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$38.51 - $48.43 $2.66 Million - $3.34 Million	69,000 Added 1.18%	5,930,006 $229 Million
Q3 2024 Nov 14, 2024	BUY	$33.72 - $47.33 $682,256 - $957,627	20,233 Added 0.35%	5,861,006 $263 Million
Q2 2024 Aug 14, 2024	BUY	$24.66 - $34.8 $2.51 Million - $3.54 Million	101,800 Added 1.77%	5,840,773 $202 Million
Q1 2024 May 15, 2024	BUY	$21.79 - $32.15 $98,991 - $146,057	4,543 Added 0.08%	5,738,973 $166 Million
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $80.6 Million - $134 Million	5,734,430 New	5,734,430 $131 Million
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $90.8 Million - $129 Million	5,446,430 New	5,446,430 $90.8 Million
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $34.2 Million - $55.7 Million	1,896,416 Added 72.52%	4,511,430 $125 Million
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $11.2 Million - $26.3 Million	-1,036,873 Reduced 28.39%	2,615,014 $60.1 Million
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $382,947 - $570,522	-48,721 Reduced 1.32%	3,651,887 $30.8 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $18.1 Million - $65.5 Million	2,566,151 Added 226.2%	3,700,608 $29.3 Million
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $18.3 Million - $28.2 Million	-782,677 Reduced 40.83%	1,134,457 $26.9 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $8.37 Million - $17.6 Million	-474,866 Reduced 19.85%	1,917,134 $65.6 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $807,044 - $3.1 Million	62,320 Added 2.68%	2,392,000 $42.4 Million
Q2 2021 Aug 13, 2021	SELL	$25.57 - $44.88 $2.44 Million - $4.28 Million	-95,320 Reduced 3.93%	2,329,680 $105 Million
Q4 2020 Feb 16, 2021	SELL	$18.49 - $25.13 $6.01 Million - $8.17 Million	-325,000 Reduced 11.82%	2,425,000 $48.9 Million
Q3 2020 Nov 16, 2020	BUY	$15.19 - $22.4 $3.8 Million - $5.6 Million	250,000 Added 10.0%	2,750,000 $53.8 Million
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $6.19 Million - $18.8 Million	1,000,000 Added 66.67%	2,500,000 $44.2 Million
Q2 2019 Aug 14, 2019	SELL	$8.98 - $12.96 $2.6 Million - $3.76 Million	-290,000 Reduced 16.2%	1,500,000 $18.2 Million
Q1 2019 May 15, 2019	SELL	$6.5 - $13.77 $2.66 Million - $5.64 Million	-409,674 Reduced 18.62%	1,790,000 $22.5 Million
Q4 2018 Feb 14, 2019	SELL	$6.3 - $10.44 $274,226 - $454,432	-43,528 Reduced 1.94%	2,199,674 $14.8 Million
Q3 2018 Nov 14, 2018	BUY	$6.82 - $11.26 $9.09 Million - $15 Million	1,332,973 Added 146.44%	2,243,202 $23.1 Million
Q2 2018 Aug 14, 2018	SELL	$5.99 - $9.1 $618,593 - $939,766	-103,271 Reduced 10.19%	910,229 $6.12 Million
Q1 2018 May 15, 2018	BUY	$8.46 - $23.08 $960,210 - $2.62 Million	113,500 Added 12.61%	1,013,500 $8.71 Million
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $13 Million - $18.7 Million	900,000	900,000 $18.7 Million

Others Institutions Holding PTGX

# of Institutions

254

Shares Held

58.9M

Call Options Held

226K

Put Options Held

218K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.89B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.

Account

Farallon Capital Management LLC Protagonist Therapeutics, Inc Transaction History